Persistent low levels of disease in bone marrow, an immunoprivileged tissue, are responsible for relapse following allogeneic hematopoietic cell transplantation. Using mouse models carrying primary human acute lymphoblast leukemia derived from MLL-AF9-overexpressing human hematopoietic stem cells, we demonstrate that allogeneic lymphocyte infusion (ALI)-mediated graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100. Adoptive transfer experiments confirmed that the frequency of leukemia-initiating cells in bone marrow was significantly decreased in the recipients treated with ALI plus AMD3100 compared to those receiving ALI only. These findings indicate that the immunoprivileged nature of bone marrow is largely responsible for relapse after immunotherapies, and that treatment with AMD3100 may offer a clinically-practical approach to improving the outcome of adoptive allogeneic cell therapy. The response rate for allogeneic hematopoietic cell transplantation (allo-HCT) or allogeneic lymphocyte infusion (ALI) varies significantly depending on underlying malignancy and responses are frequently short lived, and the residual disease in BM is considered a powerful independent prognostic factor for relapse. 9 In this study, we investigated the potential of the BM immunosuppressive status to protect leukemia cells from ALI-mediated anti-leukemia responses in a humanized mouse model of acute human lymphoblastic leukemia. We demonstrate that leukemia cells in the BM are highly resistant to ALI, and that ALI achieves a high complete remission rate in the recipients in which leukemia cells are dislodged from BM by treatment with a CXCR4
graft-vs.-leukemia effects selectively spare leukemia cells in the bone marrow. The resistance of leukemia cells to ALI within bone marrow is due to the immunosuppressive status of the tissue, as ALI achieved a significantly increased complete remission rate when leukemia cells were dislodged from bone marrow by treatment with a CXCR4 antagonist AMD3100. Adoptive transfer experiments confirmed that the frequency of leukemia-initiating cells in bone marrow was significantly decreased in the recipients treated with ALI plus AMD3100 compared to those receiving ALI only. These findings indicate that the immunoprivileged nature of bone marrow is largely responsible for relapse after immunotherapies, and that treatment with AMD3100 may offer a clinically-practical approach to improving the outcome of adoptive allogeneic cell therapy.
| I N TR ODU C TI ON
Leukemia cells hijack the normal hematopoietic stem cell (HSC) niche in the bone marrow (BM) and become leukemic stem cells (LSCs) 1, 2 that are responsible for relapse. [3] [4] [5] Although alterations of the BM niche by leukemia cells remain largely undefined, the BM niche has been shown to be essential in maintaining the function of LSCs and protect LSCs against chemotherapy. 1, 2 Recent studies provide the evidence that the BM, especially the HSC niche, is an immune privilege site and its immunosuppressive nature protects donor HSCs from alloimmune rejection. [6] [7] [8] The persistence of allogeneic HSCs in the BM of non-conditioned recipient mice for over a moth with a similar survival frequency as syngeneic HSCs demonstrated that the HSC niche provides an effective sanctuary from immune attack. 8 These observation raise a possibility that the immunosuppressive BM microenvironment may also protect leukemia cells against eradication by immunotherapies and thus lead to relapse.
The response rate for allogeneic hematopoietic cell transplantation (allo-HCT) or allogeneic lymphocyte infusion (ALI) varies significantly depending on underlying malignancy and responses are frequently short lived, and the residual disease in BM is considered a powerful independent prognostic factor for relapse. 9 In this study, we investigated the potential of the BM immunosuppressive status to protect leukemia cells from ALI-mediated anti-leukemia responses in a humanized mouse model of acute human lymphoblastic leukemia. We demonstrate that leukemia cells in the BM are highly resistant to ALI, and that ALI achieves a high complete remission rate in the recipients in which leukemia cells are dislodged from BM by treatment with a CXCR4 antagonist AMD3100. Thus, treatment with AMD3100 offers a clinically-practical approach to improving the outcome of allo-HCT. 
| M E TH ODS

| Blockade of the CXCL12/CXCR4 pathway dislodges leukemia cells from bone marrow
CXCR4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1; also called CXCL12). CXCR4 is expressed on HSCs and the CXCL12/CXCR4 axis keeps HSCs localized in the BM niche. The CXCL12/ CXCR4 axis also plays a crucial role in ALL homing to and survival in the BM, 14, 15 and high CXCR4 expression correlates with poor outcome. 16 Flow cytometric analysis confirmed that almost all leukemia (GFP 1 ) cells were CXCR4 1 (Supporting Information Figure S1A ). Leukemia cells in peripheral blood expressed a higher level of CXCR4 than those in BM (Supporting Information Figure S1B ), similar to previous observations in patients. 16 Therefore, we hypothesized that blockade of the CXCL12/CXCR4 axis can mobilize leukemia cells out of BM, thus improving the efficacy of ALI. We determined whether treatment with a CXCR4-antagonist AMD3100 can efficiently mobilize leukemia cells into circulation by measuring GFP 1 leukemic cells in peripheral blood in mice treated with 5 daily injections of AMD3100 (5mg/Kg/d) or PBS (as controls; Supporting Information Figure   S2A ). PBMCs evaluated one day prior to treatment showed comparable levels of GFP 1 leukemia cells in the two groups (Supporting Information Figure   S2B ). However, AMD3100-treated mice showed a rapid increase in the levels of GFP 1 leukemia cells in PBMCs within 3 hours after the first injection of AMD3100 (Figure 2A ,B). Although a decline was detected between 6 and 12 hours, the levels of GFP 1 leukemia cells in AMD3100-treated mice were still significantly higher than the controls at 12 hours after treatment (Figure 2A,B) . The levels of GFP 1 cells in PBMCs at 6 hours after the last Figure S2C ). Furthermore, the two groups of mice had similar levels (both percentages and cell counts) of leukemia cells in all tissues examined 4 weeks after treatment (Figure 2E ,F; Supporting Information Figure S2D ), indicating that AMD3100 did not significantly affect leukemia development in these mice.
| Blockade of the CXCL12/CXCR4 pathway improves the potency of ALI to eradicate leukemia
We then compared GVL effects between leukemic mice that received ALI alone and those treated with ALI plus AMD3100. NSG mice were injected 1x10 5 leukemia cells and followed 5 weeks later by ALI (2x10 6 allogeneic PBMCs per mouse). One group of the mice also received 5 daily injections (5mg/Kg/d) of AMD3100 starting at day 10 post-ALI ( Figure 3A ). The levels of leukemia cells in the blood were comparable between the AMD3100-treated and control groups immediately before (day 1) and 10 days after ALI (immediately before AMD3100 treatment; Figure 3B ). Both groups showed a significant decrease in the levels of leukemia cells in peripheral blood 10 days after ALI, reflecting an effective GVL effects mediated by ALI in these mice ( Figure 3B ). However, ALI resulted in complete disappearance of leukemia cells from blood only in AMD-3100-treated mice, whereas an increase in leukemia cells was detected after 15 days post-ALI in the control group (Figure 3B) . Furthermore, leukemia cells were almost undetectable in tissues, including BM, liver and kidney in AMD3100-treated mice, while large numbers of leukemia cells were detected in these tissues in the control group ( Figure 3C,D) . The two groups of mice showed no difference in the levels of human CD3 1 T cells (Supporting Information Figure S3A ) or bodyweight changes (Supporting Information Figure S3B ).
Similar results were obtained from another independent experiment, in which all mice were followed until moribund. Although the levels of leukemia cells in the blood were comparable between the two groups immediately before (day 1) and 10 days after ALI (immediately before AMD3100 treatment), the AMD3100-treated group had a significantly lower level of leukemia cells than the control group at day 15 ( Figure 3E ). Again, there was no significant difference in the levels of human CD3 1 T cells between the two groups (Supporting Information Figure S3C ). BM aspiration performed at day 25 post-ALI showed that leukemia cells were undetectable in the BM of AMD3100-treated mice, whereas detected in large numbers in the PBS controls ( Figure   3F ). With an exception of one mouse (ID 10717) that showed rapid development of GVHD (with >20% weight loss by day 19) had a minimal level of leukemia cells, large numbers of leukemia cells were detected in all tissues from moribund mice in the PBS control group ( Figure 3G ; Table 1 ). In contrast, leukemia cells were almost undetectable in these tissues from mice treated with AMD3100 ( Figure 3G ; Table 1 ). There was no correlation between mortality and leukemia burden, indicating that these mice succumbed to GVHD but not leukemia. Unlike GVL effects, the two groups had no difference in survival (Supporting Information Figure S3D ). Together, the results from these independent experiments indicate that AMD3100 treatment enhances GVL efficacy without affecting the survival or expansion of alloreactive T cells or the development of GVHD.
We also tested if second round of ALI plus AMD3100 could further enhance the anti-leukemia response. In this experiment, leukemia cells became detectable in the peripheral blood (2% of PBMCs) within 3 weeks after injection of 1x10 5 leukemia cells (about two weeks earlier than the above described experiments; Figure 3) and accordingly, the mice received the first ALI at week 3, followed 10 days later by 5 daily injections of AMD or PBS ( Figure   4A ). The levels of leukemia cells in the blood were comparable between the two groups at day 10 post-first ALI (immediately before treatment with AMD3100 or PBS), but were significantly lower in the AMD3100-treated mice than the PBS controls at day 15 post-first ALI (ie, 5 days after the first injection of AMD3100 or PBS; Figure 4B ). A significant increase in leukemia cells in the blood between day 10 and day 15 post-ALI was seen in the PBS controls, but not in ADM3100-treated mice, indicating an enhancement of GVL effects by AMD3100 treatment ( Figure 4B ). However, leukemia cells were largely detectable in the blood at day 15 in both groups ( Figure 4B ), we therefore performed second ALI from the same allogeneic donor at day 18, followed 7 days later by administration of AMD3100 or PBS ( Figure 4A ). Following second ALI, the levels of leukemia cells in the PBS controls decreased rapidly and significantly, and became comparable to those in AMD3100-treatred mice at day 25 (immediately before the second round of AMD3100 administration; Figure 4B ). However, at day 31 (6 days after starting the second round of AMD3100 treatment), the levels of circulating leukemia cells were significantly lower in AMD3100-treated (undetectable in 2 out 5 mice) than in PBS controls ( Figure 4B ). We also examined the surviving leukemia cells in tissues when mice were sacrificed 31 days after ALI. Again, ALI was markedly more effective in eradicating leukemia cells in BM, spleen, liver, and lungs in AMD3100-treated than in PBS-injected mice ( Figure 4C,D) . These data indicate that multiple rounds of AMD3100 treatment can Figure S4A,B) , or bodyweight changes of the recipients (Supporting Information Figure S4C ), consistent with the above observations (Supporting Information Figure   S3 ) that AMD3100 treatment does not significantly affect GVHD in mice following ALI. (Fig. 4A ).
We were able to collect GFP 1 leukemia cells from BM in 4 of 5 AMD3100-treated mice (GFP 1 cells were undetectable in one of these mice) for adoptive transfer, in which leukemia cells harvested from BM of 3 surviving PBS-treated mice were used as the controls (Fig. 4E-G) .
At week 5, leukemia cells were detected in the peripheral blood in all secondary recipients of GFP 1 BM cells from PBS-treated mice, but only in one of the recipients that received GFP 1 BM cells from AMD3100-treated mice, and the levels of leukemia cells remained significantly lower in the latter than the former group for at least 8 weeks (Fig. 4E) . Furthermore, mice receiving leukemia cells from AMD3100-treated mice also showed prolonged survival compared to those receiving leukemia cells from PBS-injected mice (Fig. 4F) . For the one AMD3100-treated mouse with undetectable leukemia cells, all BM clinical leukemia in patients. 10 Using this model, here we found that leukemia cells in the BM are highly resistant to the GVL effects of ALI.
Importantly, we demonstrate that dislodgement of leukemia cells from BM by blocking the CXCL12/CXCR4 pathway can markedly improve the potential of ALI to eradicate leukemia cells and achieve a significantly increased complete remission rate. Although there are might be differences in the susceptibility to ALI between BM-resident and peripheral tissue-resident/circulating leukemia cells, these data indicate that the BM is a powerful sanctuary for leukemia cells during immunotherapy.
Multiple factors are involved in creating the immunosuppressive microenvironment within BM. It has been reported that regulatory T (Treg) cells play a critical role in protection of donor HSCs from alloimmune rejection in BM. 8 The BM niche is known to be a hypoxic condition that is essential to the maintenance of stem cell quiescence. 17, 18 Hypoxia is also an immune regulatory factor that inhibits antitumor responses through multiple mechanisms, including suppressing the function of various types of immune effector cells, inducing resistance to cell-mediated cytotoxicity, and recruiting Treg cells. 7, 19 Furthermore, the stromal elements (eg, mesenchymal stromal cells; MSCs) and immature myeloid cells (eg, myeloid derived suppressive cells; MDSCs)
within BM may also contribute to its immunosuppressive property. 20, 21 Given all of the above, it is felt that dislodging leukemia cells out of the immunoprivileged BM would be a more effective and simpler approach to facilitating eradication of leukemia cells than targeting the above mentioned factors simultaneously.
AMD3100 mobilizes both HSCs and T cells, among the latter to a greater extent for effector/memory T cells and Treg cells. 22 Accordingly, it has been thought to develop mobilizing regimes that generate donor peripheral blood stem cell products enriched in Tregs for reducing GVHD. 23 Although there is likely a limitation in both numbers and function of BM Tregs in conditioned allo-HCT recipients, it is still important to determine whether AMD3100 may affect GVL effects via mobilization of Tregs. This issue was not addressed in the current study due to the use of immunodeficient recipient mice. Humanized mice with a functional human lymphohematopoietic system and autologous leukemia 11 are required for answering this question.
ALL patients respond poorly to ALI compared to patients with chronic and acute myeloid leukemia. [24] [25] [26] [27] Although it has been argued that the poor response may be due to lack of antigen presenting cell (APC) function of ALL blasts, the precise mechanisms are still undefined. Our results demonstrate that the immunoprivileged nature of BM is largely responsible for ALL relapse after ALI. ALL blasts in the BM are also likely resistant to killing by other types of promising immunotherapy, such as TCR and chimeric antigen receptor-based T cell therapies. 28 AMD3100 (Plerixafor) is one of the clinically approved drugs that have been used to mobilize normal and malignant stem cells in the clinic. 29, 30 Thus, treatment with AMD3100 either alone or in combination with other stem cell mobilization drugs may offer a potentially effective and universal approach to improving the outcome of anti-leukemia immunotherapies.
